Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro - PubMed

Affiliations

• PMID: 11814343
• DOI: 10.1021/bi011711s

Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro

Jeffrey A Cohlberg et al. Biochemistry. 2002.

Abstract

Parkinson's disease is the second most common neurodegenerative disease and results from loss of dopaminergic neurons in the substantia nigra. The aggregation and fibrillation of alpha-synuclein have been implicated as a causative factor in the disease. Glycosaminoglycans (GAGs) are routinely found associated with amyloid deposits in most amyloidosis diseases, and there is evidence to support an active role of GAGs in amyloid fibril formation in some cases. In contrast to the extracellular amyloid deposits, the alpha-synuclein deposits in Lewy body diseases are intracellular, and thus it is less clear whether GAGs may be involved. To determine whether the presence of GAGs does affect the fibrillation of alpha-synuclein, the kinetics of fibril formation were investigated in the presence of a number of GAGs and other charged polymers. Certain GAGs (heparin, heparan sulfate) and other highly sulfated polymers (dextran sulfate) were found to significantly stimulate the formation of alpha-synuclein fibrils. Interestingly, the interaction of GAGs with alpha-synuclein is quite specific, since some GAGs, e.g., keratan sulfate, had negligible effect. Heparin not only increased the rate of fibrillation but also apparently increased the yield of fibrils. The molar ratio of heparin to alpha-synuclein and the incorporation of fluorescein-labeled heparin into the fibrils demonstrate that the heparin is integrated into the fibrils and is not just a catalyst for fibrillation. The apparent dissociation constant for heparin in stimulating alpha-synuclein fibrillation was 0.19 microM, indicating a strong affinity. Similar effects of heparin were observed with the A53T and A30P mutants of alpha-synuclein. Since there is some evidence that Lewy bodies may contain GAGs, these observations may be very relevant in the context of the etiology of Parkinson's disease.

Similar articles

• Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.

  Conway KA, Harper JD, Lansbury PT Jr. Conway KA, et al. Biochemistry. 2000 Mar 14;39(10):2552-63. doi: 10.1021/bi991447r. Biochemistry. 2000. PMID: 10704204

• Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

  Conway KA, Harper JD, Lansbury PT. Conway KA, et al. Nat Med. 1998 Nov;4(11):1318-20. doi: 10.1038/3311. Nat Med. 1998. PMID: 9809558

• Dissociation of amyloid fibrils of alpha-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities.

  Foguel D, Suarez MC, Ferrão-Gonzales AD, Porto TC, Palmieri L, Einsiedler CM, Andrade LR, Lashuel HA, Lansbury PT, Kelly JW, Silva JL. Foguel D, et al. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9831-6. doi: 10.1073/pnas.1734009100. Epub 2003 Aug 4. Proc Natl Acad Sci U S A. 2003. PMID: 12900507 Free PMC article.

• Amino acid determinants of alpha-synuclein aggregation: putting together pieces of the puzzle.

  Uversky VN, Fink AL. Uversky VN, et al. FEBS Lett. 2002 Jul 3;522(1-3):9-13. doi: 10.1016/s0014-5793(02)02883-1. FEBS Lett. 2002. PMID: 12095610 Review.

• Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.

  El-Agnaf OM, Irvine GB. El-Agnaf OM, et al. J Struct Biol. 2000 Jun;130(2-3):300-9. doi: 10.1006/jsbi.2000.4262. J Struct Biol. 2000. PMID: 10940234 Review.

Cited by

• Regulation of Age-Related Protein Toxicity.

  Pras A, Nollen EAA. Pras A, et al. Front Cell Dev Biol. 2021 Mar 5;9:637084. doi: 10.3389/fcell.2021.637084. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33748125 Free PMC article. Review.

• The Non-Fibrillating N-Terminal of α-Synuclein Binds and Co-Fibrillates with Heparin.

  Skaanning LK, Santoro A, Skamris T, Martinsen JH, D'Ursi AM, Bucciarelli S, Vestergaard B, Bugge K, Langkilde AE, Kragelund BB. Skaanning LK, et al. Biomolecules. 2020 Aug 16;10(8):1192. doi: 10.3390/biom10081192. Biomolecules. 2020. PMID: 32824376 Free PMC article.

• Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson's disease.

  Rasia RM, Bertoncini CW, Marsh D, Hoyer W, Cherny D, Zweckstetter M, Griesinger C, Jovin TM, Fernández CO. Rasia RM, et al. Proc Natl Acad Sci U S A. 2005 Mar 22;102(12):4294-9. doi: 10.1073/pnas.0407881102. Epub 2005 Mar 14. Proc Natl Acad Sci U S A. 2005. PMID: 15767574 Free PMC article.

• Glycoconjugate journal special issue on: the glycobiology of Parkinson's disease.

  Brockhausen I, Schutzbach J, Wang J, Fishwick B, Brockhausen J. Brockhausen I, et al. Glycoconj J. 2022 Feb;39(1):55-74. doi: 10.1007/s10719-021-10024-w. Epub 2021 Nov 10. Glycoconj J. 2022. PMID: 34757539 Review.

• Mechanism of amylin fibrillization enhancement by heparin.

  Jha S, Patil SM, Gibson J, Nelson CE, Alder NN, Alexandrescu AT. Jha S, et al. J Biol Chem. 2011 Jul 1;286(26):22894-904. doi: 10.1074/jbc.M110.215814. Epub 2011 May 9. J Biol Chem. 2011. PMID: 21555785 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • BioCyc

• Miscellaneous

  • NCI CPTAC Assay Portal